呼吸道合胞病毒治疗药物及其作用靶点的研究进展  

Progress in studies on drugs and their target points against respiratory syncytial virus

作　　者：叶文静[1] 翁婷婷 董琳[1] Ye Wenjing;Weng Tingting;Dong Lin(Department of Pediatric Respiratory Diseases,the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University,Wenzhou 325027,China)

机构地区：[1]温州医科大学附属第二医院育英儿童医院儿童呼吸科,325027

出　　处：《中华实验和临床病毒学杂志》2020年第1期92-96,共5页Chinese Journal of Experimental and Clinical Virology

摘　　要：呼吸道合胞病毒(respiratory syncytial virus,RSV)在全球造成了严重的疾病负担,特别是在年龄小于2岁的儿童中。目前仍没有安全有效疫苗和特异性的抗病毒药物可供使用。了解病毒感染宿主细胞的机制,可为研发新型抗RSV药物提供靶点。近年来,靶向融合蛋白阻止病毒进入和靶向病毒RNA依赖的RNA聚合酶抑制病毒复制是RSV抑制剂及单克隆抗体研究热点。此外,以宿主因子为靶点研发抗RSV药物受到越来越多的关注。本文就RSV感染的致病机制、药物作用靶点及其代表药物做一概述。The global burden of disease attributable to respiratory syncytial virus(RSV)remains high,especially in children younger than 2 years old.At present,there are still no safe and effective vaccines and specific antiviral drugs available.Understanding the mechanism of virus infection in host cells can provide targets for the development of new anti-RSV drugs.In recent years,targeting fusion protein to prevent virus entry and targeting RNA-dependent RNA polymerase to inhibit virus replication have been hot spots in the research of RSV inhibitors and monoclonal antibodies.In addition,more and more attention has been paid to the development of anti-RSV drugs targeting host factors.This article explains the pathogenesis of RSV.Moreover,the drug targets and its representative drugs are listed.

关 键 词：呼吸道合胞病毒 药物靶点 病毒抑制剂 单克隆抗体 

分 类 号：R9[医药卫生—药学]